Inflammation & the cytokine route to low mood

What actually decides this outcome, in order of size

This is the only pathway in the mood goal where the causal experiment has been run in humans, in both directions, and it is also the one where the marker most often disagrees with the symptom. Ranked by how much of the outcome each one owns:

1. Whether an inflammatory driver is actually present, which is one cheap test. This page is written for the reader whose mood tracks an illness, a flare, a gut problem or a treatment. In somebody with a normal C-reactive protein and no inflammatory condition, the mechanism this page describes has nothing to act on, and every product below is being bought against a hypothesis the blood does not support.
2. That the direction of causation has been demonstrated, which almost no mechanism on this site can say. Interferon and anti-TNF therapies were shown to modulate amygdala reactivity in opposite directions, and those changes predicted bidirectional changes in depressive symptoms Davies 2021. Giving a cytokine signal produces symptoms; removing one relieves them. That is the argument, and it is stronger than anything the monoamine page can offer.
3. Which symptoms the inflammation is producing, because it is not all of them. Associations between C-reactive protein and individual symptoms of depression have been examined item by item Fellows 2024, and the inflammatory signal concentrates in the somatic items rather than in the cognitive and affective ones. A reader whose complaint is guilt and hopelessness rather than fatigue and appetite change is on the wrong mechanism.
4. Tryptophan diversion, which is the specific route from a cytokine to a mood. Indoleamine 2,3-dioxygenase is induced by inflammatory signaling and shunts tryptophan down the kynurenine pathway. Anthranilic acid, a kynurenine-pathway metabolite, has been examined for its role in the rise of depressive symptoms during interferon treatment Pawlowski 2021. That is the mechanism that connects this page to Serotonergic and explains why supplying substrate does not fix an inflammatory depression.
5. The products, last, and the class-level result is mixed rather than positive. Anti-inflammatory agents in major depressive disorder have a systematic review and meta-analysis covering both efficacy and acceptability Du 2024. Long-chain omega-3 for anxiety and depression has its own systematic review and meta-analysis of randomized trials Kelaiditis 2023. Read both before assuming the shelf is settled in either direction.

The order to run these in, and what has to be true first

Measure the inflammation, find where it is coming from, treat the source, and only then buy something that modulates it. A supplement aimed at a cytokine whose source is an untreated dental abscess or an active colitis is being asked to out-argue the thing making it.

1. hs-CRP (High-Sensitivity C-Reactive Protein) before anything else, twice, two weeks apart. Within-person variation in C-reactive protein is wide, so one value is a week rather than a state. Two concordant results are what make this page's whole premise true or false for a given reader.
2. Then find the source, which is four more analytes and a history. Complete Blood Count (CBC) with Differential with ESR (Sed Rate), ANA (Antinuclear Antibodies) and Thyroid Antibodies (TPO + TgAb) for an autoimmune process, HbA1c (Hemoglobin A1c) for the metabolic contribution, and Ferritin read alongside the CRP rather than alone. Periodontal disease, untreated sleep-disordered breathing and an inflammatory bowel condition are the three sources that most often sit behind a raised CRP in somebody who feels flat.
3. Super EPA (Fish Oil) rather than a general fish oil, and the distinction is the whole argument. The antidepressant signal in this literature is associated with EPA-predominant preparations, and the systematic review of long-chain omega-3 for anxiety and depression is the place to read what the pooled effect actually is Kelaiditis 2023. Omega-3 (Fish Oil) as a generic DHA-heavy oil is a different intervention.
4. Curcumin next, and formulation decides whether it exists systemically. Its proposed route here is nuclear factor kappa B and the same IDO step that diverts tryptophan Pawlowski 2021. Unformulated turmeric powder produces almost no free curcumin in plasma, so a phytosome or a piperine co-administration is the difference between a dose and a label.
5. NAC is a redox and glutamate argument rather than a cytokine one. N-acetylcysteine supplies cysteine for glutathione synthesis and modulates the cystine-glutamate antiporter, which is a different mechanism to everything above it and is worth keeping separate when judging what helped.
6. Probiotic and High-Potency Probiotic are strain questions, not category questions. Probiotics have been meta-analyzed for prevention in one clinical setting Hao 2015 and the manufacturing side has its own problem: a quality position paper documents products that do not contain the strains or the counts they declare Kolacek 2017. Buy the strain that was trialed or accept that you are testing something else.
7. Vitamin D belongs here and belongs low. The VITAL trial randomized vitamin D and marine omega-3 in a large population Manson 2019, and the honest position for mood is that repletion matters in the deficient and that supplementation on top of sufficiency is not where the evidence is.
8. Saffron, Palmitoylethanolamide (PEA), SPMs (Pro-Resolving Mediators), Luteolin and Low Dose Naltrexone are the glial and resolution tier. Luteolin reduces interleukin-6 production in microglia by inhibiting JNK phosphorylation and AP-1 activation Jang 2008, which is a cell-level result in a cell type that is not sampled in living people. Extending microglial modulation to a mood endpoint is extrapolation from mechanism and is not evidence.

What gets bought for this that cannot move it

The category fails first on selection: most people who buy it do not have the finding it treats. An anti-inflammatory bought for low mood in somebody with a normal C-reactive protein is being asked to lower something that is not raised. The class-level meta-analysis of anti-inflammatory agents in major depressive disorder is mixed on efficacy and reports acceptability separately Du 2024, and the trials that do find effects are enriched for people with an inflammatory finding.

C-reactive protein is the option here whose apparent relevance most exceeds its coverage. It maps onto the somatic symptom cluster more than the affective one Fellows 2024, so a falling CRP alongside unchanged low mood is the expected result rather than a failure of the marker, and a reader who set out to move a mood by moving a number has misread which symptoms the number owns.

A general fish oil is not the intervention this page describes. The signal in the depression literature attaches to EPA-predominant formulations, which is why the pooled reviews have to sort by composition rather than by grams of oil Kelaiditis 2023. A DHA-heavy capsule taken for mood is a null result about a different product, and the same logic applies to probiotic products that do not contain the trialed strain Kolacek 2017.

And if the pattern points elsewhere, this is the wrong page. Low mood with no inflammatory finding and no medical illness routes to Serotonergic. Wired and tired with a stress relationship routes to HPA axis & cortisol regulation. A raised homocysteine or a low B12 routes to Methylation & micronutrient substrate. If the inflammatory source is the gut, the source is the page: Barrier integrity & mucosal repair and Overgrowth, dysbiosis & antimicrobials outrank anything on this shelf for that reader.

How you would know it was working, on a real read-out and a real timescale

The prediction is unusually clean for a mood page. If inflammation is driving the symptoms here, hs-CRP (High-Sensitivity C-Reactive Protein) and the somatic items of the symptom score should fall together across 12 weeks, and the affective items may not move with them Fellows 2024. If hs-CRP (High-Sensitivity C-Reactive Protein) falls and nothing else does, the mechanism worked and the mechanism was not the problem.

• hs-CRP (High-Sensitivity C-Reactive Protein) at baseline (twice) and at 12 weeks. Twice at baseline because a single value carries substantial within-person variability, and because this page is only for readers in whom it is genuinely raised. Anything above 10 mg/L is an acute event and has to be repeated once it has settled rather than treated as a chronic tone.
• TNF-Alpha only if you understand what it is. It is the cytokine the causal experiment manipulated Davies 2021, and it is a research-grade analyte with poor between-day reproducibility, diurnal variation and assay-dependent reference intervals. Order it to characterize an inflammatory picture, not to grade a supplement.
• A symptom instrument scored by item, not just by total. The somatic and affective clusters behave differently against inflammation Fellows 2024, so a total score hides the exact comparison this page rests on. Fatigue, appetite change and sleep on one line; mood, interest and guilt on another.
• Vitamin D (25-Hydroxy) once, and read it against the trial rather than against a target. The large randomized evidence is where the expectation should come from Manson 2019, and the useful question is deficiency rather than optimization.
• HbA1c (Hemoglobin A1c) once, at 12 weeks if it was raised. Glycemic load is one of the commonest chronic contributors to a low-grade inflammatory tone, and it is the contributor most likely to still be there after the supplement has been running for three months.

What will fool you. Any infection, injury, dental problem or hard training block in the week before the draw raises C-reactive protein, so a follow-up taken three days after a race is measuring the race. Adiposity is a major determinant of basal CRP, so a change in body composition moves the marker without any of these products being involved. Season and viral exposure move both the marker and the mood in the same direction. And the anti-inflammatory class as a whole has mixed pooled results Du 2024, so an uncontrolled personal success is exactly the observation those trials were designed to check.

Sources read for these sections

• Davies KA. Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms. Molecular Psychiatry 2021;26(9):5150-5160 · PMID 32457424
• Pawlowski T. The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-alpha2a and oral ribavirin. Journal of Psychiatry and Neuroscience 2021;46(1):E166-E175 · PMID 33464780
• Du Y. Efficacy and acceptability of anti-inflammatory agents in major depressive disorder: a systematic review and meta-analysis. Frontiers in Psychiatry 2024;15:1407529 · PMID 38863604
• Fellows E. Associations between C-reactive protein and individual symptoms of depression in a lower-middle income country. BJPsych Open 2024;10(6):e199 · PMID 39359158
• Kelaiditis CF. Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults; A systematic review and meta-analysis of randomised controlled trials. Prostaglandins Leukotrienes and Essential Fatty Acids 2023;192:102572 · PMID 37028202
• Manson JE, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. The New England Journal of Medicine, 2019 · PMID 30415629
• Hao Q, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Systematic Reviews, 2015 · PMID 25927096
• Kolacek S. Commercial Probiotic Products: A Call for Improved Quality Control. A Position Paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 2017 · PMID 28644359
• Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences 2008 · PMID 18490655